Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Circulating tumor cell clusters-associated gene plakoglobin is a significant prognostic predictor in patients with breast cancer.

Goto W, Kashiwagi S, Asano Y, Takada K, Takahashi K, Hatano T, Takashima T, Tomita S, Motomura H, Ohsawa M, Hirakawa K, Ohira M.

Biomark Res. 2017 May 12;5:19. doi: 10.1186/s40364-017-0099-2. eCollection 2017.

2.

Breast-conserving surgery in locally advanced breast cancer submitted to neoadjuvant chemotherapy. Safety and effectiveness based on ipsilateral breast tumor recurrence and long-term follow-up.

Carrara GF, Scapulatempo-Neto C, Abrahão-Machado LF, Brentani MM, Nunes JS, Folgueira MA, Vieira RA.

Clinics (Sao Paulo). 2017 Mar;72(3):134-142. doi: 10.6061/clinics/2017(03)02.

3.

Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI).

Sajjadi AY, Isakoff SJ, Deng B, Singh B, Wanyo CM, Fang Q, Specht MC, Schapira L, Moy B, Bardia A, Boas DA, Carp SA.

Biomed Opt Express. 2017 Jan 4;8(2):555-569. doi: 10.1364/BOE.8.000555. eCollection 2017 Feb 1.

4.

Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.

Goorts B, van Nijnatten TJ, de Munck L, Moossdorff M, Heuts EM, de Boer M, Lobbes MB, Smidt ML.

Breast Cancer Res Treat. 2017 May;163(1):83-91. doi: 10.1007/s10549-017-4155-2. Epub 2017 Feb 15.

5.

Trends and controversies in multidisciplinary care of the patient with breast cancer.

Dominici LS, Morrow M, Mittendorf E, Bellon J, King TA.

Curr Probl Surg. 2016 Dec;53(12):559-595. doi: 10.1067/j.cpsurg.2016.11.003. Epub 2016 Nov 29. Review. No abstract available.

PMID:
28160790
6.

Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period.

Choi M, Park YH, Ahn JS, Im YH, Nam SJ, Cho SY, Cho EY.

J Pathol Transl Med. 2017 Jan;51(1):69-78. doi: 10.4132/jptm.2016.10.05. Epub 2016 Dec 25.

7.

Outcome after neoadjuvant chemotherapy in Asian breast cancer patients.

Lim LY, Miao H, Lim JS, Lee SC, Bhoo-Pathy N, Yip CH, Taib NA, Chan P, Tan EY, Lim SH, Lim GH, Woo E, Tan YS, Lee JA, Wong M, Tan PH, Ong KW, Wong FY, Yap YS, Hartman M.

Cancer Med. 2017 Jan;6(1):173-185. doi: 10.1002/cam4.985. Epub 2016 Dec 20.

8.
9.
11.

Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials.

Zhang ZC, Xu QN, Lin SL, Li XY.

PLoS One. 2016 Oct 14;11(10):e0164663. doi: 10.1371/journal.pone.0164663. eCollection 2016.

12.

Value of volume-based metabolic parameters for predicting survival in breast cancer patients treated with neoadjuvant chemotherapy.

Kim TH, Yoon JK, Kang DK, Kang SY, Jung YS, Han S, Kim JY, Yim H, An YS.

Medicine (Baltimore). 2016 Oct;95(41):e4605.

13.

Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer.

Fukada I, Araki K, Kobayashi K, Shibayama T, Takahashi S, Horii R, Akiyama F, Iwase T, Ohno S, Hatake K, Hozumi Y, Sata N, Ito Y.

PLoS One. 2016 Sep 15;11(9):e0162616. doi: 10.1371/journal.pone.0162616. eCollection 2016.

14.

The role of oncoplastic breast conserving treatment for locally advanced breast tumors. A matching case-control study.

Vieira RA, Carrara GF, Scapulatempo Neto C, Morini MA, Brentani MM, Folgueira MA.

Ann Med Surg (Lond). 2016 Aug 3;10:61-8. doi: 10.1016/j.amsu.2016.08.001. eCollection 2016 Sep.

15.

Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.

Loo CE, Rigter LS, Pengel KE, Wesseling J, Rodenhuis S, Peeters MJ, Sikorska K, Gilhuijs KG.

Breast Cancer Res. 2016 Aug 5;18(1):82. doi: 10.1186/s13058-016-0742-0.

16.

Platelet-Lymphocyte Ratio as a Useful Predictor of the Therapeutic Effect of Neoadjuvant Chemotherapy in Breast Cancer.

Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajiri H, Takashima T, Ohsawa M, Kitagawa S, Hirakawa K.

PLoS One. 2016 Jul 29;11(7):e0153459. doi: 10.1371/journal.pone.0153459. eCollection 2016.

17.

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.

Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken MC, D'Hondt V, De Azambuja E, Gombos A, Lebrun F, Dal Lago L, Bustin F, Maetens M, Ameye L, Veys I, Michiels S, Paesmans M, Larsimont D, Sotiriou C, Nogaret JM, Piccart M, Awada A.

PLoS One. 2016 Jul 25;11(7):e0154009. doi: 10.1371/journal.pone.0154009. eCollection 2016.

18.

Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies.

Okuma HS, Koizumi F, Hirakawa A, Nakatochi M, Komori O, Hashimoto J, Kodaira M, Yunokawa M, Yamamoto H, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Br J Cancer. 2016 Aug 9;115(4):411-9. doi: 10.1038/bjc.2016.184. Epub 2016 Jul 14.

20.

Surgical Outcomes for Mastectomy Patients Receiving Neoadjuvant Chemotherapy: A Propensity-Matched Analysis.

Bowen ME, Mone MC, Buys SS, Sheng X, Nelson EW.

Ann Surg. 2017 Mar;265(3):448-456. doi: 10.1097/SLA.0000000000001804.

Supplemental Content

Support Center